Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-04

Aclaris Therapeutics, Inc. (ACRS)

CEO Neal Walker was paid $3,375,591 in fiscal year 2025, ↑ up 133.6% from fiscal year 2024, the 29th percentile of its disclosed peer group (SEC filing 0001104659-26-047262 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,375,591 ↑
Neal Walker total, FY2025
29th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
89.54%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Neal Walker (Chief Executive Officer), FY2025 total compensation $3,375,591 (base salary $615,000) [exec_comp, SEC accession 0001104659-26-047262, filed 2026-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

ACRS's next annual pay disclosure, estimated April 22, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Neal Walker$615,000$0$828,426$1,581,615$350,550$0$0$3,375,591
Chief Executive Officer
Kevin Balthaser446,0000310,640548,440171,710014,0001,490,790
Chief Financial Officer
James Loerop416,0000336,800520,146160,160014,0001,447,106
Chief Business Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Neal Walker$3,375,591$1,445,135—↑ +1,930,456
Kevin Balthaser1,490,7901,102,1632,344,432↑ +388,627
James Loerop1,447,106—2,332,912—

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Aclaris Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ACRS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Aclaris Therapeutics, Inc. Peer Teardown Report

$3,375,591 Neal Walker total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of August 4, 2026 · Source: 0001104659-26-047262 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for ACRS

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
ACRSon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order ACRS

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against ACRS
7 companies name ACRS as a compensation peer

The list of companies that name ACRS as a peer is temporarily unavailable — recheck shortly.

Get the Aclaris Therapeutics, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Anand MehraIndependent Director$120,486
Andrew SchiffIndependent Director$100,486
Christopher MolineauxIndependent Director$141,986
Hugh DavisDirector—
Maxine GowenIndependent Director$107,986
Vincent MilanoIndependent Director$120,486
William HumphriesIndependent Director$112,486
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Braden Michael LeonardGreater-than-10% holder2026-04-23D300,000$5$1,359,000Common, indirectForm 4 ↗
Jesse Wayne HallChief Medical Officer2026-05-01D36,37500Derivative, Class A CommonForm 4 ↗
Jesse Wayne HallChief Medical Officer2026-05-01D9,330441,145CommonForm 4 ↗
Jesse Wayne HallChief Medical Officer2026-05-01A36,375——CommonForm 4 ↗
Maxine GowenDirector2026-06-04A10,98700Derivative, Class A CommonForm 4 ↗
Vincent MilanoDirector2026-06-04A42,35000Derivative, Class A CommonForm 4 ↗
William HumphriesDirector2026-06-04A10,98700Derivative, Class A CommonForm 4 ↗
Vincent MilanoDirector2026-06-04A10,98700Derivative, Class A CommonForm 4 ↗
Andrew SchiffDirector2026-06-04A10,98700Derivative, Class A CommonForm 4 ↗
Anand MehraDirector2026-06-04A10,98700Derivative, Class A CommonForm 4 ↗
Maxine GowenDirector2026-06-04A42,35000Derivative, Class A CommonForm 4 ↗
Christopher MolineauxDirector2026-06-04A10,98700Derivative, Class A CommonForm 4 ↗
Christopher MolineauxDirector2026-06-04A42,35000Derivative, Class A CommonForm 4 ↗
William HumphriesDirector2026-06-04A42,35000Derivative, Class A CommonForm 4 ↗
Andrew SchiffDirector2026-06-04A42,35000Derivative, Class A CommonForm 4 ↗
Anand MehraDirector2026-06-04A42,35000Derivative, Class A CommonForm 4 ↗
Vincent MilanoDirector2026-06-05A11,580——CommonForm 4 ↗
Christopher MolineauxDirector2026-06-05D11,58000Derivative, Class A CommonForm 4 ↗
Anand MehraDirector2026-06-05A11,580——CommonForm 4 ↗
Maxine GowenDirector2026-06-05D11,58000Derivative, Class A CommonForm 4 ↗
Maxine GowenDirector2026-06-05A11,580——CommonForm 4 ↗
Vincent MilanoDirector2026-06-05D11,58000Derivative, Class A CommonForm 4 ↗
Christopher MolineauxDirector2026-06-05A11,580——CommonForm 4 ↗
William HumphriesDirector2026-06-05D11,58000Derivative, Class A CommonForm 4 ↗
William HumphriesDirector2026-06-05A11,580——CommonForm 4 ↗
Andrew SchiffDirector2026-06-05D11,58000Derivative, Class A CommonForm 4 ↗
Andrew SchiffDirector2026-06-05A11,580——CommonForm 4 ↗
Anand MehraDirector2026-06-05D11,58000Derivative, Class A CommonForm 4 ↗
Roland Wilhelm KolbeckChief Scientific Officer2026-08-01D12,385564,402CommonForm 4 ↗
Roland Wilhelm KolbeckChief Scientific Officer2026-08-01D36,37500Derivative, Class A CommonForm 4 ↗
Roland Wilhelm KolbeckChief Scientific Officer2026-08-01A36,375——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Kevin BalthaserRSU2025-01-02——40,000—$99,200
Kevin BalthaserOPTION2025-02-03——308,200—548,440
Neal WalkerRSU2025-02-03——253,900—609,360
Neal WalkerOPTION2025-02-03——888,800—1,580,000
Kevin BalthaserRSU2025-02-03——88,100—211,440
James LoeropRSU2025-02-03——83,500—200,400
James LoeropRSU2025-01-02——55,000—136,400
James LoeropOPTION2025-02-03——292,300—520,146
Neal WalkerRSU2025-01-02——88,333—219,066
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Kevin Balthaser$310,640$0$548,4400.0%
Neal Walker828,42601,580,0000.0%
James Loerop336,8000520,1460.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Neal WalkerOption888,8002.4—
James LoeropOption154,8751.2—
Neal WalkerRSU253,900—764,239
Kevin BalthaserRSU88,100—265,181
James LoeropRSU83,500—251,335
Neal WalkerRSU59,184—178,144
Kevin BalthaserRSU44,250—133,193
James LoeropRSU44,250—133,193
James LoeropRSU36,850—110,919
Kevin BalthaserRSU26,800—80,668
Kevin BalthaserRSU15,000—45,150
James LoeropRSU15,000—45,150
James LoeropRSU11,250—33,863
Kevin BalthaserRSU2,375—7,149
Kevin BalthaserOption8,35014.94—
Kevin BalthaserOption52,50016.97—
Kevin BalthaserOption154,8751.2—
Kevin BalthaserOption308,2002.4—
James LoeropOption38,75011.58—
James LoeropOption52,50016.97—
James LoeropOption292,3002.4—
05

Incentive-plan design — the Compensation Discussion & Analysis

We consider compensation for comparable positions in the market, historical compensation levels, individual performance, and our desire to motivate employees to achieve short- and long-term results. We deliver a majority of compensation through long-term incentives.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantPearl Meyer
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0483,370,1249,734,69134,37889.54%Passed
20252025-06-0555,498,27116,981,505208,52476.57%Passed
20242024-06-0629,025,58316,273,81621,24264.07%Passed
20232023-06-0158,615,8601,232,70928,21397.94%Passed
20222022-06-0249,767,2611,004,91814,01398.02%Passed
20212021-06-0334,972,3711,308,8856,45496.39%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0489.54%a
20252025-06-0576.57%b
20242024-06-0664.07%c

a. Approved under the standard stated in the filing — “Proposal Number ​ ​ ​ Proposal Description ​ ​ ​ Vote Required for Approval ​ Voting Options ​ ​ ​ Effect of Abstentions or Withhold Votes (as Applicable) ​ ​ ​ Effect of Broker Non- Votes 1 ​ Election of Directors ​ Nominees receiving the most "For" votes ​ "For" or "Withold" ​ No effect ​ No effect 2 ​ Advisory vote to approve compensation of our named executive officers ​ "For" votes from holders of a majority of the shares present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ "For," "Against" or abstain ​ Against ​ No effect 3 ​ Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2026 ​ "For" votes from holders of a majority of the shares present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ "For," "Against" or abstain ​ Against ​ Not applicable (1) (1) This proposal is considered a "routine" matter under NYSE rules.”.

b. Approved under the standard stated in the filing — “Proposal Number Proposal Description Vote Required for Approval ​ Voting Options Effect of Abstentions or Withhold Votes (as Applicable) Effect of Broker Non- Votes 1 ​ Election of Directors ​ Nominees receiving the most "For" votes ​ "For" or "Withold" ​ No effect ​ No effect 2 ​ Advisory vote to approve compensation of our named executive officers ​ "For" votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ "For," "Against" or abstain ​ Against ​ No effect 3 ​ Charter amendment to increase authorized shares of common stock ​ "For" votes from a majority of the votes cast "For" or "Against" the proposal ​ "For," "Against" or abstain ​ No effect ​ Brokers have discretion to vote (1) 4 ​ Approval of 2025 Equity Incentive Plan ​ "For" votes from a majority of the votes cast "For" or "Against" the proposal ​ "For," "Against" or abstain ​ No effect ​ No effect 5 ​ Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2025 ​ "For" votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ "For," "Against" or abstain ​ Against ​ Brokers have discretion to vote (1) (1) This proposal is considered a "routine" matter under NYSE rules.”.

c. Approved under the standard stated in the filing — “​ ​ ​ ​ ​ ​ ​ ​ ​ Proposal Number Proposal Description Vote Required for Approval Effect of Abstentions Effect of Broker Non- Votes 1 ​ Election of Directors ​ Nominees receiving the most "For" votes ​ Not applicable ​ No effect 2 ​ Advisory vote to approve compensation of our named executive officers ​ "For" votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ Against ​ No effect 3 ​ Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024 ​ "For" votes from holders of a majority of the shares having voting power present or represented by proxy at the Annual Meeting and entitled to vote on the matter ​ Against ​ Brokers have discretion to vote (1) (1) This proposal is considered a "routine" matter under NYSE rules.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Christopher MolineauxIndependent · Audit · Governance (Chair)$81,500$18,065$42,422$0$-1$141,986
Anand MehraIndependent · Compensation (Chair)60,00018,06542,4220-1120,486
Vincent MilanoIndependent · Audit (Chair)60,00018,06542,4220-1120,486
William HumphriesIndependent · Compensation · Governance52,00018,06542,4220-1112,486
Maxine GowenIndependent · Audit47,50018,06542,4220—107,986
Andrew SchiffIndependent40,00018,06542,4220-1100,486
Hugh DavisEmployee director000—00
Neal WalkerEmployee director · Board Chair000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$320,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)12,500 / 12,500 / 4,500
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$341,000
Equity awards (grant-date value)$108,390
All other compensation$-5
Total cost of the board$449,385

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Aclaris Therapeutics, Inc.2025Neal Walker$615,000$828,426$1,581,615$350,550$3,375,591

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Aclaris Therapeutics, Inc. in fiscal 2025?
As disclosed, Neal Walker (Chief Executive Officer) was the highest-paid executive at Aclaris Therapeutics, Inc. in fiscal 2025, with total compensation of $3,375,591.
How does Aclaris Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Neal Walker's total compensation ranked at the 29th percentile of Aclaris Therapeutics, Inc.'s disclosed peer group.
How did shareholders vote on Aclaris Therapeutics, Inc.'s executive compensation?
As disclosed, 89.54% of shareholders supported Aclaris Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Aclaris Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Aclaris Therapeutics, Inc. reported total board compensation of $449,385 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Neal WalkerDEF 14A2026-04-230001104659-26-047262Section “Summary Compensation Table”. As printed: 3,375,591. Filing ↗machine: r2 · c14 · span 317880–317889
2Section 01, Kevin BalthaserDEF 14A2026-04-230001104659-26-047262Section “Summary Compensation Table”. As printed: 1,490,790. Filing ↗machine: span 325515–325524
3Section 01, James LoeropDEF 14A2026-04-230001104659-26-047262Section “Summary Compensation Table”. As printed: 1,447,106. Filing ↗machine: span 333198–333207
4Section 03, Kevin Balthaser RSUDEF 14A—0001104659-26-047262Section “THE BOARD OF DIRECTORS RECOMMENDSVOTE IN FAVOR OF PROPOSAL” · grants of plan-based awards table. Filing ↗machine: t33 · r2 · c0 · span 234777–234779
5Section 03, Kevin Balthaser OPTIONDEF 14A2026-04-230001104659-26-047262Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t56 · r4 · c8 · span 323820–323827
6Section 03, Neal Walker RSUDEF 14A2026-04-230001104659-26-047262Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 374188–374195
7Section 03, Neal Walker OPTIONDEF 14A2026-04-230001104659-26-047262Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 374283–374290
8Section 03, Kevin Balthaser RSUDEF 14A2026-04-230001104659-26-047262Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 374197–374203
9Section 03, James Loerop RSUDEF 14A2026-04-230001104659-26-047262Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 374208–374214
10Section 03, James Loerop RSUDEF 14A2026-04-230001104659-26-047262Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 375206–375212
11Section 03, James Loerop OPTIONDEF 14A2026-04-230001104659-26-047262Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t56 · r6 · c8 · span 331559–331566
12Section 03, Neal Walker RSUDEF 14A2026-04-230001104659-26-047262Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 375187–375193
13Section 07, pay ratioDEF 14A2026-04-230001104659-26-047262Section “CEO Pay Ratio”. As printed: —. Filing ↗
14Section 08, Christopher MolineauxDEF 14A2026-04-230001104659-26-047262Section “Director Compensation”. As printed: 141,986. Filing ↗machine: span 605382–605510
15Section 08, Anand MehraDEF 14A2026-04-230001104659-26-047262Section “Director Compensation”. As printed: 120,486. Filing ↗machine: span 603064–603192
16Section 08, Vincent MilanoDEF 14A2026-04-230001104659-26-047262Section “Director Compensation”. As printed: 120,486. Filing ↗machine: span 612021–612149
17Section 08, William HumphriesDEF 14A2026-04-230001104659-26-047262Section “Director Compensation”. As printed: 112,486. Filing ↗machine: span 600902–601030
18Section 08, Maxine GowenDEF 14A2026-04-230001104659-26-047262Section “Director Compensation”. As printed: 107,986. Filing ↗machine: span 609862–609990
19Section 08, Andrew SchiffDEF 14A2026-04-230001104659-26-047262Section “Director Compensation”. As printed: 100,486. Filing ↗machine: span 607527–607655
20Section 08, Hugh DavisDEF 14A2026-04-230001104659-26-047262Section “Director Compensation”. As printed: 0. Filing ↗
21Section 08, Neal WalkerDEF 14A2026-04-230001104659-26-047262Section “Director Compensation”. As printed: 0. Filing ↗
22Section 02, Braden Michael Leonard 2026-04-23Form 42026-04-270001373604-26-000034Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Jesse Wayne Hall 2026-05-01Form 42026-05-050002065269-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Jesse Wayne Hall 2026-05-01Form 42026-05-050002065269-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Jesse Wayne Hall 2026-05-01Form 42026-05-050002065269-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Maxine Gowen 2026-06-04Form 42026-06-080001280044-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Vincent Milano 2026-06-04Form 42026-06-080001187159-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, William Humphries 2026-06-04Form 42026-06-080001674278-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Vincent Milano 2026-06-04Form 42026-06-080001187159-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Andrew Schiff 2026-06-04Form 42026-06-080001172252-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Anand Mehra 2026-06-04Form 42026-06-080001590102-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Maxine Gowen 2026-06-04Form 42026-06-080001280044-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Christopher Molineaux 2026-06-04Form 42026-06-080001654773-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Christopher Molineaux 2026-06-04Form 42026-06-080001654773-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, William Humphries 2026-06-04Form 42026-06-080001674278-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Andrew Schiff 2026-06-04Form 42026-06-080001172252-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Anand Mehra 2026-06-04Form 42026-06-080001590102-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Vincent Milano 2026-06-05Form 42026-06-080001187159-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Christopher Molineaux 2026-06-05Form 42026-06-080001654773-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Anand Mehra 2026-06-05Form 42026-06-080001590102-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Maxine Gowen 2026-06-05Form 42026-06-080001280044-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Maxine Gowen 2026-06-05Form 42026-06-080001280044-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Vincent Milano 2026-06-05Form 42026-06-080001187159-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Christopher Molineaux 2026-06-05Form 42026-06-080001654773-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, William Humphries 2026-06-05Form 42026-06-080001674278-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, William Humphries 2026-06-05Form 42026-06-080001674278-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Andrew Schiff 2026-06-05Form 42026-06-080001172252-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Andrew Schiff 2026-06-05Form 42026-06-080001172252-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Anand Mehra 2026-06-05Form 42026-06-080001590102-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Roland Wilhelm Kolbeck 2026-08-01Form 42026-08-040002076327-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Roland Wilhelm Kolbeck 2026-08-01Form 42026-08-040002076327-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Roland Wilhelm Kolbeck 2026-08-01Form 42026-08-040002076327-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
53Section 06, 2026 voteForm 8-K2026-06-040001104659-26-070494Item 5.07 · say-on-pay result. As reported: 89.54% (votes for as printed: 83,370,124). Filing ↗
54Section 06, 2025 voteForm 8-K2025-06-050001558370-25-008430Item 5.07 · say-on-pay result. As reported: 76.57% (votes for as printed: 55,498,271). Filing ↗
55Section 06, 2024 voteForm 8-K2024-06-070001558370-24-009009Item 5.07 · say-on-pay result. As reported: 64.07% (votes for as printed: 29,025,583). Filing ↗
56Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
57Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
58Section 09b board cost (computed)Computed——Cash 341,000 + equity 108,390 + all other -5 = 449,385, summed across the director compensation table rows.machine: formula: Σ = 449,385
59Aclaris Therapeutics, Inc. (subject), Section 10b CEO totalDEF 14A2026-04-230001104659-26-047262CEO total compensation as printed in Aclaris Therapeutics, Inc.'s own proxy. As printed: 3,375,591. Filing ↗machine: r2 · c14 · span 317880–317889

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Aclaris Therapeutics, Inc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
ACRS Peer Teardown Report